Motilal Oswal: Biocon Biologics - Takeaways From The Management Call
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
We hosted a meeting with the management of Biocon Biologics Ltd. to get a detailed perspective on the company’s strategy.
Here are the key insights from our discussion -
On the base of $350 million in the past 12 months, Biocon plans to reach $1 billion in sales in its Biologics division by FY22.
This would be driven by increased capacity utilisation/ramp-up in the market share of already commercialized biosimilar products (Pegfilgrastim/Trastizumab) in the U.S./Europe and Most of the World markets.
This would be complemented by the recently launched Insulin Glargine.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.